NL-OMON42839招募中2 期
A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochondrial disease - The KHENERGY study
Khondrion B.V.0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Males and females aged 18 years or older at screening
- •2. Ability and willingness to sign the Informed Consent Form prior to screening evaluations.
- •3. Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation
- •4. Heteroplasmy level as measured in urine >= 20 %.
- •5. Body Mass Index (BMI) 18.0-30.0 kg/m2 (extremes included) at screening
- •6. Clinical evidence of mitochondrial disease, positive NMDAS score (including but not limited to MELAS, MIDD and mixed types). CPEO patients with signs restricted to the eye only are not considered eligible.
- •7. Disease appropriate physical and mental health as established by medical history, physical examination, electrocardiogram (ECG) and vital signs recording, and results of biochemistry, hematology and urinalysis testing within 3 weeks prior to the first dose as judged by the Investigator.
- •8. Appropriate cardiac functioning as assessed by medical history, ECG and Echo, evaluated by a cardiologist.
- •9. Able to comply with the study requirements, including exercise testing and swallowing study medication
- •10. Willingness to use adequate contraceptive methods (male and female) and negative urine pregnancy test (females) at screening and first baseline assessment.
- •11. Able and willing to refrain from the use of (multi)vitamins, co-enzyme Q10, Vitamine E, riboflavin, and anti-oxidant supplements (and idebenone/EPI-743), as well as any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and NSAID*s) as well as any strong Cytochrome P450 inhibitors (all *conazoles-anti-fungals*, HIV antivirals, grapefruit) and strong Cytochrome P450 inducers (a.o. carbamazepine, phenobarbital, phenytoin, rifampicine, St Johns wort, pioglitazone, troglitazone) as well as any medication known to affect cardiac repolarization (all anti-psychotics, several anti-depressants: nor/amytriptilline, fluoxetine, anti-emetics: domperidone (motilium) granisetron, ondansetron).
排除标准
- •1. Motoric abnormalities other than related to the mitochondrial disease interfering with the outcome parameters.
- •2. CPEO patients with clinical signs and symptoms restricted to the eye only
- •3. Heteroplasmy level as measured in urine < 20%
- •4. Poor nutritional state as judged by the investigator
- •5. Body Mass Index (BMI) not within 18.0-30.0 kg/m2 at screening.
- •6. History of cancer
- •7. Surgery or active illness of gastro-intestinal tract that might interfere with absorption.
- •8. Participation in a trial of an investigational product in the preceding 3 months prior to the first dose or during this trial.
- •9. Positive drug, alcohol or cotinine test at screening and/or admission (Day 1 of the first dosing period).
- •10. Clinically relevant abnormal laboratory, ECG recordings, cardiac echo (within 1 year prior to screening), vital signs or physical or mental findings at screening as judged by the Investigator.
- •11. Clinically relevant abnormal ECG or cardiac functioning as judged by a cardiologist.
- •12. ECG: QTc > 450 ms, abnormal T-wave
- •13. Symptomatic heart failure or signs of ischemic heart disease
- •14. Left Ventricular Ejaction Fraction <45%
- •15. History or family history of congenital Long QT syndrome
- •16. Increased or decreased potassium (local laboratory normal range)
- •17. Inadequate contraception use, pregnancy or breast feeding (females)
- •18. Clinically significant presence or history of allergy as judged by the Investigator.
- •19. History of hypersensitivity or idiosyncrasy to any of the components of the investigational drug.
- •20. Within 4 weeks prior to dosing, the use of (multi)vitamins, co-enzyme Q10, Vitamine E, riboflavin, and anti-oxidant supplements (and idebenone/EPI-743), as well as any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and NSAID*s) as well as any strong Cytochrome P450 inhibitors (all *conazoles-anti-fungals*, HIV antivirals, grapefruit) and strong Cytochrome P450 inducers (a.o. carbamazepine, phenobarbital, phenytoin, rifampicine, St Johns wort, pioglitazone, troglitazone) as well as any medication known to affect cardiac repolarization (all anti-psychotics, several anti-depressants: nor/amytriptilline, fluoxetine, anti-emetics: domperidone (motilium) granisetron, ondansetron)
研究者
相似试验
招募中
1 期
To evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TX000045 (single ascending dose) in Healthy VolunteersCardiovascularCardiovascular - Other cardiovascular diseasesRespiratory - Other respiratory disorders / diseasesACTRN12623001054606Tectonic Therapeutic48
进行中（未招募）
1 期
A Phase II study with KH176 in patients with mitochondrial diseaseInherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness)EUCTR2016-001696-79-NLKhondrion BV
已完成
不适用
A double-blind, placebo-controlled, randomized, single and multiple ascending dose study of the safety and tolerability, and pharmacokinetics (including food effect, pH effect and Japanese bridging study) of BMS-986337 following oral administration in healthy participantsidiopathic pulmonary fibrosisNL-OMON49565Bristol-Myers Squibb Research and Development78
已完成
不适用
A double-blind, placebo-controlled, randomized, single and multiple ascending dose study (including food effect, pH effect, and Japanese bridging Study) of the safety, pharmacokinetics, and exploratory pharmacodynamics of oral BMS-986278 administration in healthy participants10010613Idiopathic pulmonary fibrosisNL-OMON46573Bristol-Myers Squibb Research and Development62
尚未招募
不适用
A double-blind, randomized, placebo controlled, single oral dose, two way cross-over trial to investigate the effects of an orally administered 5-HTP challenge test on hypothalamic fMRS activation in healthy male volunteers.depressionunipolar depressive disorder10027946NL-OMON31533Centre for Human Drug Research6